Last reviewed · How we verify
Trastuzumab Biosimilar ABP 980 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Trastuzumab Biosimilar ABP 980 (Trastuzumab Biosimilar ABP 980) — West German Study Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trastuzumab Biosimilar ABP 980 TARGET | Trastuzumab Biosimilar ABP 980 | West German Study Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trastuzumab Biosimilar ABP 980 CI watch — RSS
- Trastuzumab Biosimilar ABP 980 CI watch — Atom
- Trastuzumab Biosimilar ABP 980 CI watch — JSON
- Trastuzumab Biosimilar ABP 980 alone — RSS
Cite this brief
Drug Landscape (2026). Trastuzumab Biosimilar ABP 980 — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-biosimilar-abp-980. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab